Evidence map›Paper›PMID 33891248›Full record

ArticleCardiovascular drugs and therapy2021

Ang II Promotes SUMO2/3 Modification of RhoGDI1 Through Aos1 and Uba2 Subunits, and then Regulates RhoGDI1 Stability and Cell Proliferation.

Yan Qi, Haijing Guan, Xiuying Liang, Jingwen Sun, Wenjuan Yao

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yan Qi *Department of Pharmacology, School of pharmacy, Nantong University, 19 QiXiu Road, Nantong, 226001, Jiangsu, China.
Haijing Guan *Department of Pharmacology, School of pharmacy, Nantong University, 19 QiXiu Road, Nantong, 226001, Jiangsu, China.
Xiuying LiangDepartment of Pharmacology, School of pharmacy, Nantong University, 19 QiXiu Road, Nantong, 226001, Jiangsu, China.
Jingwen SunDepartment of Pharmacology, School of pharmacy, Nantong University, 19 QiXiu Road, Nantong, 226001, Jiangsu, China.
Wenjuan YaoDepartment of Pharmacology, School of pharmacy, Nantong University, 19 QiXiu Road, Nantong, 226001, Jiangsu, China. yaowenjuan0430@aliyun.com.ORCID 0000-0001-7291-1450
Nantong University · CN

Funding

Key University Science Research Project of Jiangsu Province 19KJA320010National Natural Sciences Foundation of China 81970226Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX19_2085Research project of Nantong Health Committee QA2020006
6 · The paper itself

Abstract

purposeAng II regulates RhoGDI1 stability and cell proliferation via SUMOylation. However, how Ang II regulates RhoGDI1 SUMOylation remains unknown. In this study, we focused on revealing the effects of E1 subunits (Aos1 and Uba2) on RhoGDI1 SUMOylation in HA-VSMC proliferation.

methodsThe expressions of Aos1, Uba2, and SUMO1 were suppressed by siRNA transfection. HA-VSMCs were treated with Ang II (100 nM) for 24 h. RhoGDI1 SUMOylation and ubiquitination were checked by co-immunoprecipitation. Cell proliferation was detected by EdU assay.

resultsUba2 or Aos1 suppression significantly inhibited Ang II-induced SUMO2/3 modification of RhoGDI1 and cell proliferation, while not affecting SUMO1 modification of RhoGDI1. In addition, Uba2 or Aos1 suppression promoted RhoGDI1 ubiquitination and degradation. These indicate that both Uba2 and Aos1 are necessary for SUMO2/3 modification of RhoGDI1 that participates in cell proliferation by regulating RhoGDI1 ubiquitination and stability. Moreover, SUMO1 suppression did not affect RhoGDI1 ubiquitination and degradation and cell proliferation in Ang II-induced VSMCs, suggesting that SUMO1 modification does not participate in RhoGDI1 stability and cell proliferation.

conclusionThis study reveals the differences between SUMO2/3 and SUMO1 modification in regulating RhoGDI1 stability and Ang II-mediated cell proliferation. Schematic summary of roles of SUMO1 and SUMO2/3 modification of RhoGDI1 in regulating RhoGDI1 stability and cell proliferation in Ang II-treated HA-VSMCs.

Indexed as

Angiotensin IICell ProliferationHumansMuscle ContractionMuscle, Smooth, VascularReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2rho Guanine Nucleotide Dissociation Inhibitor alphaSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSumoylationUbiquitin-Activating EnzymesUbiquitinationUbiquitinsAngiotensin IIReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2rho Guanine Nucleotide Dissociation Inhibitor alphaSAE1 protein, humanSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSUMO1 protein, humanSUMO2 protein, humanSUMO3 protein, humanUBA2 protein, humanUbiquitin-Activating EnzymesUbiquitinsE1 activating enzymeRhoGDI1SUMOVSMC proliferation

Identifiers

PMID33891248
OpenAlexW3154341844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.